U.S. Markets closed

Idenix Reports In-Line 4Q Loss

Zacks Equity Research

Idenix Pharmaceuticals’ (IDIX) loss of 17 cents per share in the fourth quarter of 2012 was a penny below the year-ago loss and in-line with the Zacks Consensus Estimate.

The company’s fourth quarter 2012 revenues were $0.3 million up from ($0.7) million in the year-ago period, but below the Zacks Consensus Estimate of $1 million. Revenues in the year-earlier period suffered from a charge against revenues worth $3.4 million.

Full-year 2012 adjusted net loss came in at 21 cents per share, narrower than the year-ago loss of 57 cents and the Zacks Consensus Estimate of a loss of 25 cents per share.

Full-year revenues came in at $69.7 million, significantly above $6.9 million in 2011. This massive increase was due to the recognition of $36.1 million as deferred revenues in relation to the termination of a license agreement with ViiV Healthcare Company.

Full-year revenues were slightly below the Zacks Consensus Estimate of $70 million.

The Quarter in Detail

Research and development expense during the quarter increased 37.2% year over year to $17.5 million.

General and administrative expense increased 67.4% year over year to $7.3 million.

Pipeline Update

In Jan 2013, Idenix inked a collaboration agreement with Janssen Pharmaceuticals, Inc.− a Johnson & Johnson (JNJ) company – for the development of all-oral direct acting antiviral (:DAA) Hepatitis C Virus (:HCV) therapies. The collaboration covers IDIX719, simeprevin (TMC435) and TMC647055. The drug-drug interaction study is expected to begin in the first quarter of 2013.

Idenix will also file an investigational new drug application (IND) for uridine-based nucleotide analog candidate in the first half of 2013.

Idenix, a biopharma company, currently carries a Zacks Rank #3 (Hold). Other biopharma stocks like Cytokinetics Incorporated (CYTK) and Array BioPharma Inc. (ARRY) currently look more favorable. Cytokinetics carries a Zacks Rank #1 (Strong Buy), whereas Array carries a Zacks Rank #2 (Buy).

Read the Full Research Report on IDIX

Read the Full Research Report on JNJ

Read the Full Research Report on CYTK

Read the Full Research Report on ARRY

Zacks Investment Research

More From Zacks.com